{"product_id":"pt141-10mglibido-booster-re-usable-pen-kit","title":"Libido Boost Pen","description":"\u003cp\u003e\u003cstrong\u003eThe Libido Pen\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eUnderstanding PT141:\u003c\/strong\u003e\u003cbr\u003eThis product is a reusable pen system, which uses refill cartridges for precise and convenient delivery.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct Strength:\u003c\/strong\u003e 10mg per 3ml cartridge\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eStorage: \u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan\u003eKeep at room temperature\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e between \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e20–25 °C \u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003eto maintain potency and stability.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eWhat It Is\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003ePT-141 (bremelanotide) is a synthetic heptapeptide and a melanocortin receptor (MCR) agonist. It is a cyclic peptide analog derived from alpha-melanocyte-stimulating hormone (α-MSH), which was originally developed as a derivative of the research compound Melanotan II.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eThe discovery of PT-141's effects on sexual function came from an unexpected observation during early tanning research: a researcher who inadvertently took a high dose of Melanotan II experienced a prolonged erection, leading to the development of PT-141 as a targeted treatment for sexual dysfunction. In June 2019, the U.S. Food and Drug Administration (FDA) approved bremelanotide under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003ePT-141 functions as a non-selective agonist at melanocortin receptors, with its primary clinical activity attributed to activation of the MC3R and MC4R subtypes in the central nervous system. Unlike traditional treatments for erectile dysfunction (such as PDE5 inhibitors like Viagra) that work by increasing blood flow to the genitals, PT-141 acts centrally in the brain to influence sexual desire and arousal at the neurological level.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eBy activating MC4 receptors in the hypothalamus, particularly in the medial preoptic area (MPOA), PT-141 triggers a cascade of neurochemical events that increase dopamine release in brain regions responsible for sexual motivation and reward processing, including the nucleus accumbens and ventral tegmental area. This central action enables PT-141 to enhance sexual desire independently of sexual stimulation, addressing both the mental and physical components of sexual function.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4\u003e\u003cspan\u003eKey Research Applications \u0026amp; Uses\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eFDA-Approved Indication:\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eHypoactive Sexual Desire Disorder (HSDD) in premenopausal women: PT-141 is approved for the treatment of acquired, generalized HSDD characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of medication or drug substance\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eOff-Label \u0026amp; Research Uses:\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eErectile Dysfunction (ED) in men: PT-141 is used off-label to treat erectile dysfunction, particularly in men who do not respond adequately to conventional PDE5 inhibitors. A double-blind, placebo-controlled study found that approximately 80% of men developed an erection satisfactory for intercourse after using PT-141\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eLow libido in men: The peptide is also used to enhance sexual desire and motivation in men experiencing low libido, regardless of the underlying cause\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eFemale Sexual Arousal Disorder (FSAD): Beyond HSDD, research has explored PT-141's potential benefits for general female sexual arousal disorders\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eCombination therapy: Emerging evidence suggests PT-141 may provide synergistic effects when used alongside PDE5 inhibitors (e.g., sildenafil, tadalafil) for patients with partial responses to either treatment alone\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cspan\u003eAdministration \u0026amp; Dosage\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003ePT-141 is typically administered via subcutaneous injection, though compounded intranasal formulations are also available.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eTiming: \u003c\/strong\u003eAdminister at least 45 minutes (range: 30 minutes to 1 hour) before anticipated sexual activity\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eFrequency: \u003c\/strong\u003eDo not use more than one dose within 24 hours. The safety of using more than 8 doses per month has not been established\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eOnset \u0026amp; Duration:\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eOnset:\u003c\/strong\u003e Effects typically begin within 30–60 minutes\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eDuration:\u003c\/strong\u003e Effects can last between 6 to 12 hours, with some users reporting residual effects for up to 24 hours\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4\u003e\u003cspan\u003eContraindications \u0026amp; Precautions\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003ePT-141 is \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003econtraindicated\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e in individuals with the following conditions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eUncontrolled hypertension or cardiovascular disease:\u003c\/strong\u003e PT-141 causes a transient increase in blood pressure and a decrease in heart rate after administration. It should not be used in individuals with uncontrolled high blood pressure or known cardiovascular disease\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003ePregnancy:\u003c\/strong\u003e PT-141 is contraindicated during pregnancy. Women of reproductive potential should use effective contraception\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Known allergy to bremelanotide or any component of the formulation\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eSevere renal or hepatic impairment:\u003c\/strong\u003e Use with caution as drug exposure may be increased\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eConcurrent use with naltrexone:\u003c\/strong\u003e PT-141 may reduce the levels and effectiveness of naltrexone. Avoid using these drugs together\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4\u003e\u003cspan\u003eAdverse Reactions \u0026amp; Side Effects\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003eThe most common side effects associated with PT-141 are generally mild to moderate and include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eNausea: The most frequent side effect, occurring in up to 40% of users. It may last for more than two hours but often improves with subsequent doses\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eFlushing: A feeling of warmth and redness of the skin, occurring in 20–21% of users\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eHeadache: Mild to moderate, occurring in 11–12% of users\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eInjection site reactions: Redness, pain, or irritation at the injection site\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eVomiting: Less common\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eDizziness: Less common\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eStuffy nose\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eTiredness or fatigue\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eTingling sensation in fingers and toes\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eIncreased heart rate\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003eNervousness\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan\u003eLong-Term or Rare Side Effects:\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eHyperpigmentation: \u003c\/strong\u003eDarkening of the skin on the face, gums, or breasts, particularly with frequent use (more than 8 doses per month). This change may not be fully reversible after discontinuation\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan\u003e\u003cstrong\u003eTransient increases in blood pressure: \u003c\/strong\u003eTemporary but clinically significant increases in blood pressure have been observed\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong style=\"font-size: 0.875rem;\"\u003eDisclaimer:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong style=\"font-size: 0.875rem;\"\u003eThis information is for general knowledge and educational purposes only and does not constitute medical advice.  Always consult with a qualified medical professional regarding any cosmetic or medical procedure.\u003c\/strong\u003e\u003c\/p\u003e","brand":"All Peptides","offers":[{"title":"Default Title","offer_id":51877786550554,"sku":null,"price":1550.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0987\/8926\/1594\/files\/istockphoto-481482618-612x612.jpg?v=1779272972","url":"https:\/\/allpeptides.co.za\/products\/pt141-10mglibido-booster-re-usable-pen-kit","provider":"All Peptides","version":"1.0","type":"link"}